This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Anticoagulants Industry

corresponding Graph/Chart) II-83

 

Table 18: World 15-Year Perspective for Unfractionated Heparin

by Geographic Region/ Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-84

 

Table 19: World Recent Past, Current & Future Analysis for Low

Molecular Weight Heparin by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) II-85

 

Table 20: World Historic Review for Low Molecular Weight

Heparin by Geographic Region/Country - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-86

 

Table 21: World 15-Year Perspective for Low Molecular Weight

Heparin by Geographic Region/Country - Percentage Breakdown of

Dollar Sales for US, Japan, Europe, and Rest of World Markets

for Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) II-87

 

 

III. MARKET

 

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Atrial Fibrillation - A Key Risk Factor III-1

Price Controls III-1

US Anticoagulants Market III-2

FDA Approved Anticoagulants III-2

Table 22: Novel Drugs/Drug Candidates in the US

Anticoagulants Market III-3

Table 23: US Vitamin K Antagonists Market (2011):

Percentage Breakdown of Value Sales by Drug- Coumadin,

Warfarin Generics and Others (includes corresponding

Graph/Chart) III-3

 

Table 24: US Direct Thrombin (II) Inhibitors Market (2011):

Percentage Breakdown of Value Sales by Drug - Pradaxa,

Angiomax, Argatroban, Refludan and Others (includes

corresponding Graph/Chart) III-3

 

Table 25: US Market for Xarelto (2011): Percentage Share

Breakdown of Sales by Indication- Atrial Fibrillation and

8 of 15

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs